DURECT

DRRX NASDAQ
0.9710
+0.2444
+33.64%
Closed 19:59 07/22 EDT
Open
0.8001
Prev Close
0.7266
High
1.050
Low
0.8001
Volume
13.17M
Avg Vol (3M)
1.16M
52 Week High
1.660
52 Week Low
0.4600
% Turnover
6.88%
Market Cap
185.75M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers DURECT DRRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
MORE >

Recently

Name
Price
%Change